Jove
Visualize
Contact Us

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Identification Of Patl1 As A Prognostic And Immunotherapeutic Predictive Factor For Nasal-type Natural Killer/t-cell Lymphoma And Head And Neck Squamous Cell Carcinoma.
  1. Home
  3. Identification Of Patl1 As A Prognostic And Immunotherapeutic Predictive Factor For Nasal-type Natural Killer/t-cell Lymphoma And Head And Neck Squamous Cell Carcinoma.

Related Experiment Video

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas
07:00

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Published on: February 28, 2019

5.8K

Identification of PATL1 as a prognostic and immunotherapeutic predictive factor for nasal-type natural killer/T-cell

Wen Yang1,2, Cong Peng3, Zhengyang Li3

  • 1Department of Pathology, Affiliated Hospital of Guizhou Medical University, China.

Heliyon
|June 24, 2024

View abstract on PubMed

Summary
This summary is machine-generated.
Keywords:
Head and neck squamous cell carcinomaImmunotherapyNasal-type natural killer/T-cell lymphomaPATL1Prognosis

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K
A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma
08:59

A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma

Published on: January 5, 2017

10.6K

Related Experiment Videos

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas
07:00

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Published on: February 28, 2019

5.8K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K
A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma
08:59

A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma

Published on: January 5, 2017

10.6K

Protein associated with topoisomerase II homolog 1 (PATL1) is upregulated in nasal-type natural killer/T-cell lymphoma and head and neck squamous cell carcinoma. PATL1 shows potential as a prognostic and predictive biomarker for these cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Nasal-type natural killer/T-cell lymphoma (NKTCL) and head and neck squamous cell carcinoma (HNSCC) are significant health concerns.
  • Identifying novel biomarkers for diagnosis and prognosis is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the role of protein associated with topoisomerase II homolog 1 (PATL1) in NKTCL and HNSCC.
  • To evaluate PATL1 as a potential prognostic and predictive biomarker in these cancers.

Main Methods:

  • Bulk RNA-sequencing analysis of tumor and normal tissues.
  • Machine learning for hub gene identification.
  • Prognostic analysis using TCGA and GEO datasets.
  • Correlation analysis with immune cell infiltrates and gene expression.
  • In vitro cellular experiments using gene silencing.

    • Main Results:

    • PATL1 was significantly upregulated in NKTCL and HNSCC tissues, demonstrating high diagnostic accuracy for NKTCL.
    • High PATL1 expression correlated with poorer prognosis in both NKTCL and HNSCC.
    • PATL1 showed associations with immune cell infiltration, immune checkpoints, and N6-methyladenosine-related genes.
    • PATL1 expression potentially predicts immunotherapy efficacy.
    • Silencing PATL1 inhibited malignant behaviors in cancer cell lines.

    Conclusions:

    • PATL1 is a potential prognostic biomarker for NKTCL and HNSCC.
    • PATL1 may serve as a predictive biomarker for immunotherapy response.
    • PATL1 plays a significant role in the development and progression of NKTCL and HNSCC.